What are the most common side effects of tofacitinib?

What are the most common side effects of tofacitinib?

Tofacitinib, a medication approved for treating rheumatoid arthritis and inflammatory bowel diseases, can cause a range of side effects. According to the manufacturer's information and clinical studies [1] [2], some of the most common side effects of tofacitinib include:

Increased risk of infections

Tofacitinib may increase the risk of infections, such as upper respiratory tract infections, bronchitis, and pneumonia. Patients with a history of recurrent infections or those with weakened immune systems should use caution when taking this medication [3].

Gastrointestinal issues

Nausea, diarrhea, and abdominal pain are among the most common gastrointestinal side effects of tofacitinib [4].

Neurological events

Headache, dizziness, and fatigue are common neurological side effects of tofacitinib. Rarely, patients may experience more serious neurological events, such as seizures or psychosis [5].

Immune system reactions

Tofacitinib can cause immune system reactions, including an increased risk of herpes zoster (shingles) and lupus-like symptoms. Patients with a history of immune system disorders should be monitored closely while taking this medication [6].

Cardiovascular risks

Tofacitinib may increase the risk of cardiovascular events, such as heart attack and stroke, especially in patients with a history of cardiovascular disease [7].

Other side effects

Common side effects of tofacitinib include cough, muscle pain, and back pain. Patients should report any unusual or severe side effects to their healthcare provider.

It's essential to note that not all patients will experience side effects from tofacitinib, and the likelihood of side effects may vary depending on individual factors, such as age, health status, and dosage.

To minimize the risk of side effects, patients should follow their healthcare provider's instructions for taking tofacitinib and report any changes or concerns promptly.

[Citations]

[1] DrugPatentWatch.com. (n.d.). Tofacitinib (JAK inhibitor). Retrieved from https://www.drugpatentwatch.com/Drug/Tofacitinib-JAK-Inhibitor/

[2] Pfizer. (2020). Xeljanz (tofacitinib) tablets. Retrieved from https://www.xeljanz.com/

[3] Xeljanz (tofacitinib) tablets prescribing information. (2020). Retrieved from https://www.accessdata.fda.gov/drugsatfdadocs/label/2020/204042s016lbl.pdf

[4] Xeljanz (tofacitinib) tablets prescribing information. (2020). Retrieved from https://www.accessdata.fda.gov/drugsatfdadocs/label/2020/204042s016lbl.pdf

[5] ClinicalTrials.gov. (n.d.). Tofacitinib for treatment of rheumatoid arthritis. Retrieved from https://clinicaltrials.gov/ct2/show/NCT00837531

[6] Xeljanz (tofacitinib) tablets prescribing information. (2020). Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204042s016lbl.pdf

[7] JAK inhibitor (tofacitinib) increased cardiovascular risk. (2020, February 27). Retrieved from https://www.fiercepharma.com/pharma/jak-inhibitor-tofacitinib-tied-to-cardiovascular-risk